Gbr 1302

The company is expecting strong growth in the current fiscal both from India and US. Major approvals are expected to drive growth for Glenmark, says Chairman and Managing Director Glenn Saldanha.

Glenmark Pharma at new high, up 4% on foray into oncology

GBR 1302 was discovered and developed by Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland and would be first molecule to could become a patented molecule or drug for the company once it goes through multiple stages of research and development.

GBR 1302 could be an out-licencing opportunity: Glenmark

GBR 1302 molecule is a genetically engineered molecule and will be used for the study of breast cancer, says Michael Buschle.

Glenmark enters oncology segment with discovery of GBR 1302

GBR 1302 was discovered and developed by Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland and would be first molecule to could become a patented molecule or drug for the company once it goes through multiple stages of research and development.